Project Grant R01AR086310
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $497K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Southwestern Medical Center $613,036 on August 1, 2026, for investigator-initiated research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, "Leveraging Lymphatics to Reverse Heterotopic Ossification," addresses the pathologic formation of extra-skeletal bone occurring in approximately twenty percent of patients following hip...
- The National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Texas A&M University System Health Science Center $114,073 on September 23, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds investigation of sympathetic signaling as a mechanism underlying bone loss following spinal cord injury. The research comprises two aims: determining spinal-cord-injury-level-dependent effects of...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor College of Medicine $374,000 on August 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of the transcription factor TONEBP/NFAT5 in regulating chondrocyte energy availability and extracellular matrix synthesis during postnatal bone growth. The research examines how chondrocytes balance intense matrix production with protein quality...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $129,330 on September 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate molecular and physiological regulation of mRNA trafficking and translation in osteocyte dendrites. The project examines how osteocytes regulate gene and protein expression with...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Pennsylvania $2.298 million on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into osteocyte peri-lacunar and canalicular remodeling mechanisms in maternal bone adaptation during pregnancy, lactation, and post-lactation phases. The project investigates how the female skeleton undergoes bone loss and microstructural...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $124,875 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate muscle-to-bone communication during fracture repair and musculoskeletal regeneration. The research identifies pro-regenerative signals from injured muscle that orchestrate repair of both bone and muscle tissue. Preliminary findings...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $448,563 on September 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for an ancillary study investigating systemic bone loss mechanisms following fracture. UCSF will conduct multimodal analysis of circulating cells and factors in blood samples collected from fracture patients at multiple timepoints...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Southern California Institute For Research And Education $337,072 on June 19, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into the cellular and molecular mechanisms of CCDC120-associated osteopetrosis, a novel form of X-linked osteopetrosis. The research examines how loss of the CCDC120 gene and its binding partner CYTOHESIN-2 in osteoclast...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on November 16, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate mechanosensation in fibro-adipogenic progenitors during skeletal muscle regeneration. The project will elucidate how muscle-resident mesenchymal stromal cells sense mechanical changes in their environment through...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $547,767 to the University of Rochester on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate host mechanisms governing Staphylococcus aureus persistence during implant-associated osteomyelitis. The research uses humanized mouse models and multi-omic analysis of human T cells to understand why some patients resolve acute bone infections while others...